FourThought Financial’s Iovance Biotherapeutics IOVA Stock Holding History

FourThought Financial’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$26K	Buy	2,717 +56	+2%	+$646	﹤0.01%	797
2022 Q2	$29K	Buy	2,661 +218	+9%	+$2.86K	﹤0.01%	773
2022 Q1	$41K	Buy	2,443 +550	+29%	+$8.51K	0.01%	725
2021 Q4	$36K	Sell	1,893 -231	-11%	-$5.09K	﹤0.01%	770
2021 Q3	$52K	Buy	2,124 +150	+8%	+$3.53K	0.01%	679
2021 Q2	$51K	Sell	1,974 -36	-2%	-$936	0.01%	698
2021 Q1	$63K	Sell	2,010 -188	-9%	-$7.79K	0.01%	626
2020 Q4	$101K	Buy	+2,198	New	+$87.3K	0.02%	478

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

FourThought Financial's IOVA Position: Q3 2022 in Review

FourThought Financial increased its Iovance Biotherapeutics (IOVA) stake by 2.1% in Q3 2022, buying an estimated $646 and bringing the position to 2,717 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #797.

FourThought Financial first reported a position in IOVA in Q4 2020 and has held it in 8 quarters since. The position peaked at $101K in Q4 2020. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

FourThought Financial held 2,717 shares of Iovance Biotherapeutics worth $26K as of Q3 2022.
FourThought Financial bought 56 Iovance Biotherapeutics shares in Q3 2022, an estimated $646.
Iovance Biotherapeutics made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #797 holding.
FourThought Financial first reported a position in Iovance Biotherapeutics in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Iovance Biotherapeutics position peaked at $101K in Q4 2020.
242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.